Harpoon Therapeutics Overview
- Founded
-
2015

- Status
-
Public
- Employees
-
104

- Stock Symbol
-
HARP

- Share Price
-
$2.14
- (As of Monday Closing)
Harpoon Therapeutics General Information
Description
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 131 Oyster Point Boulevard
- Suite 300
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Harpoon Therapeutics Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.14 | $2.09 | $1.73 - $9.94 | $70.8M | 33.1M | 214K | -$2.31 |
Harpoon Therapeutics Financials Summary
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | (37,473) | 108,429 | 280,813 | 258,213 |
Revenue | 23,018 | 23,654 | 17,444 | 5,777 |
EBITDA | (73,890) | (114,261) | (48,857) | (55,648) |
Net Income | (75,906) | (116,721) | (49,908) | (55,572) |
Total Assets | 108,951 | 155,452 | 171,592 | 176,604 |
Total Debt | 11,399 | 12,187 | 13,515 | 14,944 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Harpoon Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Harpoon Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Harpoon Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell
Drug Discovery
South San Francisco, CA
104
As of 2022
00000
00000000
00000
Harpoon Therapeutics Competitors (93)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Instil Bio | Formerly VC-backed | Dallas, TX | 000 | 00000 | 00000000 | 00000 |
00000000 | Formerly VC-backed | San Carlos, CA | 00 | 00000 | 000000000 | 00000 |
000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
00000000 000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 - | 00000 |
000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
Harpoon Therapeutics Patents
Harpoon Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220098311-A1 | Flt3 binding proteins and methods of use | Pending | 21-Feb-2020 | 00000000000 | |
US-20210261671-A1 | Flt3 binding proteins and methods of use | Granted | 21-Feb-2020 | 000000000 | |
US-11180563-B2 | Flt3 binding proteins and methods of use | Active | 21-Feb-2020 | 000000000 | |
JP-2022502371-A | Pll3-binding protein and usage | Pending | 25-Sep-2018 | 000000000000 | |
EP-3856771-A4 | Dll3 binding proteins and methods of use | Pending | 25-Sep-2018 | A61K39/39591 |
Harpoon Therapeutics Executive Team (9)
Harpoon Therapeutics Board Members (14)
Name | Representing | Role | Since |
---|---|---|---|
Alan Colowick MD | Harpoon Therapeutics | Board Member | 000 0000 |
Andrew Robbins | Harpoon Therapeutics | Board Member | 000 0000 |
Jo Viney Ph.D | Self | Board Member | 000 0000 |
Jonathan Drachman MD | Self | Board Member | 000 0000 |
Joseph Bailes | Harpoon Therapeutics | Board Member | 000 0000 |